Oxford BioDynamics Plc is a biotechnology company specializing in the development of epigenetic biomarkers for use in precision medicine, particularly in oncology and autoimmune diseases. Its proprietary EpiSwitch technology platform differentiates it by enabling the discovery of novel biomarkers that can predict disease progression and treatment response, primarily targeting markets in the United States and Europe.
Business Overview
Oxford BioDynamics generates revenue primarily through its biomarker discovery services, which leverage its EpiSwitch technology to provide insights for pharmaceutical companies and research institutions. The company has established partnerships with major pharmaceutical firms, enhancing its pricing power and competitive position in the market.
Advancements in EpiSwitch technology leading to new partnerships
Regulatory approvals for biomarkers in clinical trials
Revenue growth from existing contracts
Market adoption of precision medicine solutions
Risk Factors
Regulatory changes affecting biomarker validation processes
Technological disruption from competing biomarker technologies
Emergence of new competitors with similar technologies
Potential for larger pharmaceutical companies to develop in-house capabilities
High debt levels relative to equity, which could strain liquidity
Negative cash flow impacting operational flexibility
Macro Sensitivity
moderate - The biotechnology sector is somewhat insulated from economic cycles, but funding for R&D can be affected by overall economic conditions.
Higher interest rates could increase the cost of capital for Oxford BioDynamics, potentially impacting its ability to finance R&D and operations, which could affect growth prospects.
minimal
Profile
growth - Investors looking for high-growth opportunities in the biotech sector will find Oxford BioDynamics appealing due to its innovative technology.
high - The stock has shown significant volatility, reflecting both the high-risk nature of biotech investments and the company's operational challenges.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
